NCT00216463 - Safety and Tolerability of Varying Load and Dose of ISIS 301012 in People With Elevated LDL-cholesterol Levels | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

August 31, 2007

Conditions

Hypercholesterolemia

Interventions

DRUG

ISIS 301012 or Placebo

200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 200 mg subcutaneous injection - every other week for 11 weeks

DRUG

ISIS 301012 or Placebo

200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 100 mg subcutaneous injection - every other week for 11 weeks

DRUG

ISIS 301012 or Placebo

300 mg subcutaneous injection - every week for 13 weeks

DRUG

ISIS 301012 or Placebo

400 mg subcutaneous injection - every week for 13 weeks

DRUG

ISIS 301012 or Placebo

200 mg subcutaneous injection - every week for 13 weeks

Trial Locations (1)

Berlin